HighTower Advisors’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

HighTower Advisors’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-461	Closed	-$5K	–	3790
2023 Q1	$5K	Sell	461 -10	-2%	-$133	﹤0.01%	3236
2022 Q4	$6K	Hold	471	–	–	﹤0.01%	3204
2022 Q3	$22K	Sell	471 -232	-33%	-$16.1K	﹤0.01%	2967
2022 Q2	$61K	Buy	703 +100	+17%	+$8.55K	﹤0.01%	2882
2022 Q1	$91K	Hold	603	–	–	﹤0.01%	3009
2021 Q4	$180K	Hold	603	–	–	﹤0.01%	2809
2021 Q3	$237K	Buy	603 +107	+22%	+$45.6K	﹤0.01%	2588
2021 Q2	$210K	Buy	496 +122	+33%	+$52.8K	﹤0.01%	2634
2021 Q1	$181K	Buy	+374	New	+$191K	﹤0.01%	2641

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

HighTower Advisors's FNCH Position: Q2 2023 in Review

HighTower Advisors sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2023, closing a stake of 461 shares — an estimated $5K sold.

HighTower Advisors first reported a position in FNCH in Q1 2021 and held it in 9 quarters. The position peaked at $237K in Q3 2021. 17 funds tracked by Wall St. Rank hold FNCH as of Q2 2023.

HighTower Advisors reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
HighTower Advisors sold 461 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2023, an estimated $5K.
HighTower Advisors first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
HighTower Advisors's Finch Therapeutics Group, Inc. Common Stock position peaked at $237K in Q3 2021.
17 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2023.

Based on HighTower Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.